Legal Representation
Attorney
Clay Shorrock
USPTO Deadlines
Next Deadline
1204 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2022-10-25)
Due Date
October 25, 2028
Grace Period Ends
April 25, 2029
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
50 events| Date | Code | Type | Description |
|---|---|---|---|
| Oct 25, 2022 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Oct 25, 2022 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Sep 20, 2022 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| Sep 19, 2022 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| Aug 12, 2022 | ALIE | A | ASSIGNED TO LIE |
| Aug 12, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Aug 12, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Aug 9, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Feb 9, 2022 | CNRT | W | SU - NON-FINAL ACTION - WRITTEN |
| Feb 9, 2022 | GNRT | O | NON-FINAL ACTION E-MAILED |
| Feb 9, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Jan 21, 2022 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE |
| Jan 19, 2022 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Jan 3, 2022 | EISU | I | TEAS STATEMENT OF USE RECEIVED |
| Jan 3, 2022 | IUAF | S | USE AMENDMENT FILED |
| Jul 3, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Jul 1, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Jul 1, 2021 | EXT4 | S | SOU EXTENSION 4 FILED |
| Jul 1, 2021 | EX4G | S | SOU EXTENSION 4 GRANTED |
| Jan 5, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Dec 31, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Dec 31, 2020 | EXT3 | S | SOU EXTENSION 3 FILED |
| Dec 31, 2020 | EX3G | S | SOU EXTENSION 3 GRANTED |
| Jul 4, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Jul 2, 2020 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Jul 2, 2020 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Jul 2, 2020 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Jul 2, 2020 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Jul 2, 2020 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Jul 2, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Jul 2, 2020 | EXT2 | S | SOU EXTENSION 2 FILED |
| Jul 2, 2020 | EX2G | S | SOU EXTENSION 2 GRANTED |
| Jan 1, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Dec 30, 2019 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Dec 30, 2019 | EXT1 | S | SOU EXTENSION 1 FILED |
| Dec 30, 2019 | EX1G | S | SOU EXTENSION 1 GRANTED |
| Jul 2, 2019 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| May 7, 2019 | PUBO | A | PUBLISHED FOR OPPOSITION |
| May 7, 2019 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| May 7, 2019 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| May 7, 2019 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Apr 17, 2019 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Mar 27, 2019 | ALIE | A | ASSIGNED TO LIE |
| Mar 7, 2019 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Mar 5, 2019 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Mar 4, 2019 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Mar 4, 2019 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Jan 14, 2019 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Jan 14, 2019 | GNRT | F | NON-FINAL ACTION E-MAILED |
| Jan 14, 2019 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
Detailed Classifications
Class 001
Biological preparations for use in industry and science; nucleic acid for laboratory use
First Use Anywhere:
Sep 18, 2018
First Use in Commerce:
Jul 31, 2021
Class 005
Biological preparations for the treatment of cancer; nucleic acid sequences and chemical reagents for medical and veterinary purposes
First Use Anywhere:
Sep 18, 2018
First Use in Commerce:
Jul 31, 2021
Class 040
Manufacturing of DNA expression vectors for others
First Use Anywhere:
Sep 18, 2018
First Use in Commerce:
Jul 31, 2021
Class 042
Scientific research; biotechnology research and development; biological research; biomedical research; research and development services in the field of DNA based medications and therapies; DNA expression vector design and development for others; biotech and clinical research and development of DNA based medications and therapies
First Use Anywhere:
Sep 18, 2018
First Use in Commerce:
Jul 31, 2021
Classification
International Classes
001
005
040
042